CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation

NCT06465537 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Open Angle Glaucoma

Interventions

GENETIC: BD113vVLP

Sponsor

Shanghai BDgene Co., Ltd.

Collaborators

[object Object]